

1 Research article

2

3 **Dry loop-mediated isothermal amplification assay for detection of SARS-CoV-2 from**
4 **clinical specimens**

5

6 Yuki Higashimoto^{1*}, Masaru Ihira², Yoshiki Kawamura³, Masato Inaba⁴, Kazuya Shirato⁵,
7 Tadaki Suzuki⁶, Hideki Hasegawa⁷, Tsutomu Kageyama⁷, Yohei Doi⁴, Tadayoshi Hata⁸, and
8 Tetsushi Yoshikawa³

9

10 ¹ Faculty of Medical Technology, Fujita Health University School of Health Sciences,
11 Toyoake, Aichi, Japan

12 ² Faculty of Clinical Engineering, Fujita Health University School of Health Sciences,
13 Toyoake, Aichi, Japan

14 ³ Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi,
15 Japan

16 ⁴ Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake,
17 Aichi, Japan

18 ⁵ Department of Virology III, National Institute of Infectious Diseases, Musashimurayama,
19 Tokyo, Japan

20 ⁶ Department of Pathology, National Institute of Infectious Diseases, Musashimurayama,

21 Tokyo, Japan

22 ⁷ Influenza Virus Research Center, National Institute of Infectious Diseases,

23 Musashimurayama, Tokyo, Japan

24 ⁸ Department of Clinical Laboratory, Fujita Health University Hospital, Toyoake, Japan

25

26

27 * Corresponding Author

28 E-mail: yhigashi@fujita-hu.ac.jp (YH)

29 **Abstract**

30 Coronavirus disease 2019 (COVID-19) has had a major disease burden on many countries around
31 the world. The spread of COVID-19 is anticipated to have a major impact on developing countries
32 including African nations. To establish a point-of-care test for COVID-19, we developed a dry
33 loop-mediated isothermal amplification (LAMP) method to detect severe acute respiratory
34 syndrome coronavirus 2 (SARS-CoV-2) RNA. We carried out reverse transcription (RT)-LAMP
35 using the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan). The entire mixture
36 except for the primers is dried and immobilized inside the tube lid. To determine the specificity of
37 the kit, 22 viral genomes associated with respiratory infections, including the SARS coronavirus,
38 were tested. No LAMP product was detected in reactions performed with RNA from these
39 pathogens. The sensitivity of this assay, determined by either a real-time turbidity assay or
40 colorimetric change of the reaction mixture, as evaluated by the naked eye or under illumination
41 with ultraviolet light, was 10 copies/reaction. After the initial validation analysis, we analyzed 24
42 nasopharyngeal swab specimens collected from patients suspected to have COVID-19. Nineteen
43 (79.2%) of the 24 samples were positive for SARS-CoV-2 RNA, as determined by real-time
44 RT-PCR analysis. Using the Loopamp SARS-CoV-2 Detection kit, we detected SARS-CoV-2 RNA
45 in 15 (62.5%) of the 24 samples. Thus, the sensitivity, specificity, positive predictive value, and
46 negative predictive value of the Loopamp 2019-CoV-2 detection reagent kit were 94.0%, 96.0%,
47 95.9%, and 94.1%, respectively. The dry LAMP method for detection of SARS-CoV-2 RNA was
48 fast and easy to use, solves the cold chain problem, and therefore represents a promising tool for

49 diagnosis of COVID-19 in developing countries.

50

51 **Author summary**

52 Coronavirus disease 2019 (COVID-19) is a major public health problem around the world. A
53 reliable point-of-care (POC) test for severe acute respiratory syndrome coronavirus 2 (SARS
54 CoV-2) is urgently needed, especially in developing countries. The loop-mediated isothermal
55 amplification (LAMP) method amplifies template nucleotides under isothermal conditions with
56 high efficiency and specificity, both of which are major advantages for a POC test. In addition,
57 because dry LAMP reagents can be stored at 4°C, it is suitable for use in developing countries.

58 We evaluated the specificity and sensitivity of the Loopamp SARS-CoV-2 Detection kit (Eiken
59 Chemical, Tokyo, Japan), a dry LAMP method for amplifying viral RNA. The initial validation
60 study revealed that the method was highly specific and sensitive (lower detection limit: 10
61 copies/reaction). We then analyzed 24 nasopharyngeal swab specimens from patients suspected to
62 have COVID-19. Using the Loopamp SARS-CoV-2 Detection kit, SARS-CoV-2 RNA was detected
63 in 15 (62.5%) of the 24 samples. Compared with the standard real-time reverse transcription PCR,
64 the sensitivity, specificity, positive predictive value, and negative predictive value of the Loopamp
65 SARS-CoV-2 Detection kit were 78.9%, 100%, 100%, and 55.6%, respectively.

66

67 **Introduction**

68

69 The outbreak of coronavirus disease 2019 (COVID-19), caused by the novel coronavirus designated
70 as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in Wuhan, China, in
71 December 2019 [1, 2]. To date, the outbreak has spread rapidly around the world [1, 2], and WHO
72 has declared it a pandemic. Clinical trials have evaluated several drugs to date, with remdesivir and
73 systemic corticosteroids showing promise for moderate and severe diseases, respectively [3].
74 Several characteristic clinical findings, such as fever and dry cough with typical signs of pneumonia
75 on chest computed tomography [4-6], history of close contact with a patient or visits to endemic
76 areas [7, 8], are useful in diagnosing COVID-19. However, many patients have mild symptoms or
77 are asymptomatic, hampering accurate diagnosis based on clinical features [9-11]. Therefore, a
78 rapid diagnostic method is necessary in order to provide definitive diagnosis of COVID-19.

79 Real-time reverse transcription–polymerase chain reaction (RT-PCR) is widely used for
80 diagnosis of COVID-19 [12, 13]. The method is very useful for testing large numbers of samples at
81 large hospitals, diagnostic companies, and local health facilities. However, a point-of-care (POC)
82 test for COVID-19 is also important for management of suspected patients in less resourced settings.
83 In addition, because expansion of COVID-19 to developing countries is a major public health
84 concern, there is an urgent need to develop rapid diagnostic tests for COVID-19. Real-time RT-PCR
85 requires a special thermal cycler with precision optics that monitor fluorescence emission from
86 sample wells. By contrast, the loop-mediated isothermal amplification (LAMP) method can amplify

87 template nucleotides under isothermal conditions with efficiency and specificity as high as those of
88 nested double PCR [14]. Due to its speed, ease of use, and cost-effectiveness, LAMP has been
89 widely used for POC testing for various infectious diseases, including COVID-19 [14-17].
90 Furthermore, the dry LAMP reagent mixture, which can be stored at 4°C, is much easier to handle
91 and more heat-stable than liquid reagents. Therefore, the dry LAMP method would very useful for
92 diagnosis of tropical infectious diseases in regions including Africa [18], which is expected to be the
93 next epicenter of COVID-19. The aim of this study was to evaluate the performance of the LAMP
94 method using dry reagents for rapid diagnosis of COVID-19 infection. Although several studies
95 have already been published on the use of LAMP to detect SARS-CoV-2 [19-21], this is the first
96 study to evaluate the performance of dry LAMP reagents for this purpose.

97

98 **Materials and methods**

99

100 **Viruses and RNA for initial validation analysis**

101 A total of 22 respiratory pathogens were used for the initial validation analysis of specificity of the
102 primers in this study. Twenty-two viral genomes are listed in Table 1. The Middle East respiratory
103 syndrome coronavirus (MERS-CoV) EMC strain was kindly provided from Dr. Ron A. M. Fouchier,
104 Erasmus Medical Center, Rotterdam, the Netherlands. The SARS-CoV Frankfurt 1 strain was
105 kindly provided from J. Ziebuhr, University of Würzburg, Germany. The clinical isolates of Human
106 coronaviruses (HCoV)-HKU1, OC43, NL63, and 229E were described by previous study [22-24].
107 *In vitro* transcribed RNA (GenBank accession number MN908947), synthesized using ScriptMax
108 Thermo T7 Transcription Kit (TOYOBO, Osaka, Japan), was used to determine the detection limit
109 of the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan).

110

111 **Clinical specimens**

112 From March 7 to April 30, 2020, nasopharyngeal swabs were collected from patients suspected to
113 have COVID-19 at a university hospital in Japan. Swab samples were collected using a flocced
114 sterile plastic swab applicator and placed in 3 mL of BD universal viral transport medium (Becton,
115 Dickinson and Company, Franklin Lakes, NJ, USA). RNA was extracted from the swab samples
116 immediately. This study was approved by the institutional review board of Fujita Health University
117 (No. HM19-493). Written informed consent was obtained from each patient.

118

119 **RNA extraction**

120 Viral RNA was extracted from 140 μ L of BD universal viral transport medium in which a
121 nasopharyngeal swab was immersed. RNA extraction was performed using the QIAamp Viral
122 RNA mini kit (QIAGEN, Chatsworth, CA, USA). After extraction, RNA was eluted in 60 μ L of
123 buffer AVE and stored at -80°C .

124

125 **Real-time RT-PCR**

126 Real-time RT-PCR assays for detecting SARS-CoV-2 were performed using TaqMan Fast Virus
127 1-Step Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). Primers and probes were as
128 follows: NIID_2019-nCOV_N_F2, 5'-AAATTTTGGGGACCAGGAAC-3';

129 NIID_2019-nCOV_N_R2, 5'- TGGCAGCTGTGTAGGTCAAC-3'; NIID_2019-nCOV_N_P2; 5'-
130 FAM ATGTCGCGCATTGGCATGGA BHQ-3' [25]. Single-well denaturation, reverse transcription,

131 and amplification steps were performed on a QuantStudio 1 Real-Time PCR System (Thermo
132 Fisher Scientific, Waltham, MA, USA) in the standard mode. Primer and probe concentrations were

133 as follows: NIID_2019-nCOV_N_F2, 500 nM; NIID_2019-nCOV_N_R2, 700 nM;

134 NIID_2019-nCOV_N_P2, 200 nM. PCR conditions were as follows: RT at 50 $^{\circ}\text{C}$ for 5 min;
135 enzyme activation at 95 $^{\circ}\text{C}$ for 20 sec; and 45 cycles of denaturation at 95 $^{\circ}\text{C}$ for 15 sec and primer

136 annealing/extension/fluorescence emission at 60 $^{\circ}\text{C}$ for 60 sec. The real-time RT-PCR reaction

137 mixture (20 μ L total volume) contained 5.0 μ L of 4 \times Fast Virus Master Mix, 1.0 μ L of

138 primer–probe pre-mix, 5.0 µL of template RNA and nuclease-free water.

139

140 **Reverse Transcription–LAMP**

141 Reverse transcription (RT)-LAMP was carried out using the Loopamp SARS-CoV-2 Detection kit
142 (Eiken Chemical). Because the entire mixture except the primers is dried and immobilized inside
143 the tube lid, 10 microliters of purified RNA and 15 microliters of SARS-CoV-2 specific primer sets
144 were added to the bottom of the tube, and then the tube was inverted several times to resuspend the
145 enzyme and buffer. The full reaction mixture was collected at the bottom of the tube by a quick
146 spin-down. The mixture was incubated in a real-time turbidimeter (LA-200; Eiken Chemical) for 35
147 min at 62.5°C. For visual evaluation of fluorescence, the reaction tube was illuminated with
148 ultraviolet light using an ultraviolet illumination system (WSE-5300; ATTO, Tokyo, Japan) and and
149 also observed by the naked eye.

150

151 **Results**

152

153 **Specificity and sensitivity of LAMP methods.**

154 To determine the specificity of the Loopamp SARS-CoV-2 Detection kit, we tested 22 viral
155 genomes including SARS coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus,
156 other human coronaviruses, influenza viruses, and respiratory syncytial viruses associated with
157 respiratory infections (Table 1). No LAMP product was detected in reactions performed with RNA
158 from these pathogens. These results were confirmed by a turbidity assay and agarose gel
159 electrophoresis analysis (data not shown). To determine the sensitivity of the Loopamp
160 SARS-CoV-2 Detection kit, *in vitro* transcribed RNAs were serially diluted in 10 mM Tris buffer
161 containing 0.1 mM EDTA and 50 ng/mL of carrier RNA were used to define the detection limit. The
162 sensitivity of this assay, determined by either the turbidity assay or colorimetric change of the
163 reaction mixtures evaluated by the naked eye, was 10 copies/reaction (Fig. 1).

164

165 **Evaluation of clinical applications**

166 To evaluate the performance of the Loopamp SARS-CoV-2 Detection kit as a POC test, we
167 analyzed 24 nasopharyngeal specimens collected from patients suspected of having COVID-19,
168 including three asymptomatic individuals who came into close contact with COVID-19 patients
169 (Table 2). Nineteen (79.2%) of the 24 samples were positive for SARS-CoV-2 RNA by real-time
170 RT-PCR analysis. Using the Loopamp SARS-CoV-2 Detection kit, SARS-CoV-2 RNA was detected

171 in 15 (62.5%) of the 24 samples. The four false-negative samples contained low copies of viral
172 RNA (2.6, 2.3, 2.2, and 0.5 copies/reaction) and were collected during the convalescent phase of
173 illness (days 7 to 20). Thus, the sensitivity, specificity, positive predictive value, and negative
174 predictive value of the Loopamp SARS-CoV-2 Detection kit were 78.9%, 100%, 100%, and 55.6%,
175 respectively.

176

177 **Discussion**

178

179 Ease of use, speed, and low cost of amplifying target nucleotides is a significant advantage of the
180 LAMP assay as a POC test. Accordingly, several investigators have developed SARS-CoV-2 LAMP
181 assays [16, 19-21, 26]. To further leverage the advantages of the LAMP method, several
182 improvements have been reported, including colorimetric detection using the naked eye [20] or
183 fluorescent detector [26] and direct detection of target sequence without RNA extraction. These
184 improvements shorten and simplify the workflow of the LAMP method [20], and enable
185 high-throughput analysis. Using the LAMP method with dry reagents allows the use of this assay in
186 developing countries, as the reagents can be stored in refrigerators that overcomes the requirement
187 for strict cold-chain transportation and storage of the reagents. Therefore, in this study, we
188 investigated the performance of the SARS-CoV-2 dry LAMP method.

189 No amplification was observed with other viral genomes (including SARS coronavirus,
190 MARS coronavirus, and other human coronaviruses associated with respiratory infections) using
191 the SARS-CoV-2 dry LAMP method (Table 1), indicating that this LAMP assay can specifically
192 amplify SARS-CoV-2. In addition, the detection limit of the kit, based on the turbidity assay and
193 colorimetric change determined by the naked eye, was 10 copies/reaction, almost the same or
194 slightly higher than the previously reported SARS-CoV-2 LAMP assays [26]. These initial
195 validation analysis demonstrated that the SARS-CoV-2 dry LAMP method is highly specific and
196 sensitive. Huang et al. have shown that SARS-CoV-2 RNA can be amplified by the LAMP assay

197 without RNA extraction [20], in line with our previous studies for detection of herpes simplex virus
198 [27] and human herpesvirus-6 [28] . Therefore, to further improve the LAMP method as a POC test,
199 a direct detection method should be developed.

200 In order to evaluate the performance of SARS-CoV-2 dry LAMP for analyzing clinical
201 samples, we analyzed 24 nasopharyngeal swab specimens collected from patients suspected of
202 having COVID-19. The sensitivity and specificity of this assay was sufficient for practical purposes.
203 In 24 nasopharyngeal swab specimens, there are only 5 SARS-CoV-2 RNA negative samples. While
204 there were 4 false-negative test results, as shown in Table 2, they represented specimens with the
205 lowest copy numbers. In particular, two of the four false-negative samples were collected on days
206 18 and 20 to confirm the absence of viral genome prior to hospital discharge. Given that all samples
207 with more than 4.4 copies/reaction were detected by both turbidity assay and colorimetric changes,
208 we believe that this SARS-CoV-2 dry LAMP method is reliable for clinical use in diagnosing
209 COVID-19.

210 In summary, this study demonstrated that the SARS-CoV-2 dry LAMP method is a reliable
211 method for rapid diagnosis of COVID-19. The dry LAMP method overcomes the requirement for
212 strict cold-chain transportation and storage of reagents. Therefore, this method is expected to be a
213 useful POC test in developing countries where COVID-19 is spreading.

214

215 **Acknowledgments**

216 We gratefully acknowledge Eiken Chemical for their contributions to this work.

217

218 **Grant support**

219 This work was supported by the Japan Agency for Medical Research and Development
220 (nos. 19fk0108030j0001, JP19fk0108104, JP19fk0108110, JP19fk0108150, 20fk0108117j0001, and
221 20fk0108117j0101). This study was also supported by a Health Labour Sciences Research Grant
222 (19HA1003).

223 **Figure Legend**

224

225 **Figure 1. Sensitivity of the SARS-CoV-2 dry LAMP assay, determined using serially**

226 **diluted *in vitro* transcribed RNA.** (a) Naked-eye detection at the end of assay (35 min).

227 Green indicates a positive reaction, and orange indicates a negative reaction. (b) Ultraviolet

228 light detection at the end of the assay (35 min). Light gray indicates a positive reaction, and

229 dark gray indicates a negative reaction. (C) Real-time turbidity assay.

230

231 **References**

- 232 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
233 associated with human respiratory disease in China. *Nature*. 2020;579(7798):265-9. Epub
234 2020/02/06. doi: 10.1038/s41586-020-2008-3. PubMed PMID: 32015508; PubMed Central
235 PMCID: PMC7094943.
- 236 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
237 associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
238 Epub 2020/02/06. doi: 10.1038/s41586-020-2012-7. PubMed PMID: 32015507; PubMed
239 Central PMCID: PMC7095418.
- 240 3. Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential
241 Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical
242 Research. *In Vivo*. 2020;34(3 Suppl):1597-602. Epub 2020/06/07. doi:
243 10.21873/invivo.11949. PubMed PMID: 32503817.
- 244 4. Liu M, Zeng W, Wen Y, Zheng Y, Lv F, Xiao K. COVID-19 pneumonia: CT findings
245 of 122 patients and differentiation from influenza pneumonia. *Eur Radiol*. 2020. Epub
246 2020/05/14. doi: 10.1007/s00330-020-06928-0. PubMed PMID: 32399710; PubMed Central
247 PMCID: PMC7216854.
- 248 5. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81

- 249 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis.*
250 2020;20(4):425-34. Epub 2020/02/28. doi: 10.1016/S1473-3099(20)30086-4. PubMed PMID:
251 32105637; PubMed Central PMCID: PMC7159053.
- 252 6. Wang H, Wei R, Rao G, Zhu J, Song B. Characteristic CT findings distinguishing
253 2019 novel coronavirus disease (COVID-19) from influenza pneumonia. *Eur Radiol.*
254 2020;30(9):4910-7. Epub 2020/04/24. doi: 10.1007/s00330-020-06880-z. PubMed PMID:
255 32323011; PubMed Central PMCID: PMC7175830.
- 256 7. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of
257 COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective
258 cohort study. *Lancet Infect Dis.* 2020;20(8):911-9. Epub 2020/05/01. doi:
259 10.1016/S1473-3099(20)30287-5. PubMed PMID: 32353347; PubMed Central PMCID:
260 PMC7185944.
- 261 8. Ding J, Tuan WJ, Temte JL. Managing Close Contacts of COVID-19 Confirmed
262 Cases in Metropolitan Areas in China. *J Public Health Manag Pract.* 2020;26(4):345-8. Epub
263 2020/04/26. doi: 10.1097/PHH.0000000000001189. PubMed PMID: 32332481; PubMed
264 Central PMCID: PMC7252620.
- 265 9. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A Locally Transmitted Case of
266 SARS-CoV-2 Infection in Taiwan. *N Engl J Med.* 2020;382(11):1070-2. Epub 2020/02/13.

267 doi: 10.1056/NEJMc2001573. PubMed PMID: 32050059; PubMed Central PMCID:
268 PMCPMC7121202.

269 10. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al.
270 Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J
271 Med. 2020;382(10):970-1. Epub 2020/02/01. doi: 10.1056/NEJMc2001468. PubMed PMID:
272 32003551; PubMed Central PMCID: PMCPMC7120970.

273 11. Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the
274 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the
275 Incubation Period. J Infect Dis. 2020;221(11):1757-61. Epub 2020/02/19. doi:
276 10.1093/infdis/jiaa077. PubMed PMID: 32067043; PubMed Central PMCID:
277 PMCPMC7107453.

278 12. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in
279 Different Types of Clinical Specimens. JAMA. 2020. Epub 2020/03/12. doi:
280 10.1001/jama.2020.3786. PubMed PMID: 32159775; PubMed Central PMCID:
281 PMCPMC7066521.

282 13. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection
283 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).
284 Epub 2020/01/30. doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID:

285 31992387; PubMed Central PMCID: PMC6988269.

286 14. Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated isothermal amplification
287 (LAMP): principle, features, and future prospects. *J Microbiol.* 2015;53(1):1-5. Epub
288 2015/01/06. doi: 10.1007/s12275-015-4656-9. PubMed PMID: 25557475.

289 15. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct
290 detection of *Mycobacterium tuberculosis* complex, *M. avium*, and *M. intracellulare* in sputum
291 samples. *J Clin Microbiol.* 2003;41(6):2616-22. Epub 2003/06/07. doi:
292 10.1128/jcm.41.6.2616-2622.2003. PubMed PMID: 12791888; PubMed Central PMCID:
293 PMC6988269.

294 16. Nzelu CO, Caceres AG, Guerrero-Quincho S, Tineo-Villafuerte E, Rodriguez-Delfin
295 L, Mimori T, et al. A rapid molecular diagnosis of cutaneous leishmaniasis by colorimetric
296 malachite green-loop-mediated isothermal amplification (LAMP) combined with an FTA card
297 as a direct sampling tool. *Acta Trop.* 2016;153:116-9. Epub 2015/10/31. doi:
298 10.1016/j.actatropica.2015.10.013. PubMed PMID: 26516109.

299 17. Higashimoto Y, Kawamura Y, Kuboshiki A, Hattori F, Miura H, Nishimura N, et al.
300 Reliability of direct varicella zoster virus loop-mediated isothermal amplification method for
301 rapid diagnosis of breakthrough varicella. *J Clin Virol.* 2019;119:53-8. Epub 2019/09/07. doi:
302 10.1016/j.jcv.2019.07.009. PubMed PMID: 31491710.

- 303 18. Hayashida K, Kajino K, Hachaambwa L, Namangala B, Sugimoto C. Direct blood
304 dry LAMP: a rapid, stable, and easy diagnostic tool for Human African Trypanosomiasis.
305 PLoS Negl Trop Dis. 2015;9(3):e0003578. Epub 2015/03/15. doi:
306 10.1371/journal.pntd.0003578. PubMed PMID: 25769046; PubMed Central PMCID:
307 PMC4358998.
- 308 19. Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, et al. A
309 colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in
310 clinical samples. Sci Transl Med. 2020;12(556). Epub 2020/07/29. doi:
311 10.1126/scitranslmed.abc7075. PubMed PMID: 32719001.
- 312 20. Huang WE, Lim B, Hsu CC, Xiong D, Wu W, Yu Y, et al. RT-LAMP for rapid
313 diagnosis of coronavirus SARS-CoV-2. Microb Biotechnol. 2020;13(4):950-61. Epub
314 2020/04/26. doi: 10.1111/1751-7915.13586. PubMed PMID: 32333644; PubMed Central
315 PMCID: PMC7264870.
- 316 21. Yu L, Wu S, Hao X, Dong X, Mao L, Pelechano V, et al. Rapid Detection of
317 COVID-19 Coronavirus Using a Reverse Transcriptional Loop-Mediated Isothermal
318 Amplification (RT-LAMP) Diagnostic Platform. Clin Chem. 2020;66(7):975-7. Epub
319 2020/04/22. doi: 10.1093/clinchem/hvaa102. PubMed PMID: 32315390; PubMed Central
320 PMCID: PMC7188121.

- 321 22. Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer
322 cell-surface TMPRSS2 to endosomal cathepsins for cell entry. *Virology*. 2018;517:9-15. Epub
323 2017/12/09. doi: 10.1016/j.virol.2017.11.012. PubMed PMID: 29217279; PubMed Central
324 PMCID: PMC7112029.
- 325 23. Kazuya S, Nao N, Matsuyama S, Kageyama T. Ultra-Rapid Real-Time RT-PCR
326 Method for Detecting Middle East Respiratory Syndrome Coronavirus Using a Mobile PCR
327 Device, PCR1100. *Jpn J Infect Dis*. 2020;73(3):181-6. Epub 2019/12/26. doi:
328 10.7883/yoken.JJID.2019.400. PubMed PMID: 31875608.
- 329 24. Shirato K, Kawase M, Watanabe O, Hirokawa C, Matsuyama S, Nishimura H, et al.
330 Differences in neutralizing antigenicity between laboratory and clinical isolates of
331 HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike
332 protein. *J Gen Virol*. 2012;93(Pt 9):1908-17. Epub 2012/06/08. doi: 10.1099/vir.0.043117-0.
333 PubMed PMID: 22673931.
- 334 25. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of
335 Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan.
336 *Jpn J Infect Dis*. 2020;73(4):304-7. Epub 2020/02/20. doi: 10.7883/yoken.JJID.2020.061.
337 PubMed PMID: 32074516.
- 338 26. Yan C, Cui J, Huang L, Du B, Chen L, Xue G, et al. Rapid and visual detection of

339 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal
340 amplification assay. *Clin Microbiol Infect.* 2020;26(6):773-9. Epub 2020/04/11. doi:
341 10.1016/j.cmi.2020.04.001. PubMed PMID: 32276116; PubMed Central PMCID:
342 PMCPMC7144850.

343 27. Enomoto Y, Yoshikawa T, Ihira M, Akimoto S, Miyake F, Usui C, et al. Rapid
344 diagnosis of herpes simplex virus infection by a loop-mediated isothermal amplification
345 method. *J Clin Microbiol.* 2005;43(2):951-5. Epub 2005/02/08. doi:
346 10.1128/JCM.43.2.951-955.2005. PubMed PMID: 15695716; PubMed Central PMCID:
347 PMCPMC548035.

348 28. Ihira M, Akimoto S, Miyake F, Fujita A, Sugata K, Suga S, et al. Direct detection of
349 human herpesvirus 6 DNA in serum by the loop-mediated isothermal amplification method. *J*
350 *Clin Virol.* 2007;39(1):22-6. Epub 2007/03/23. doi: 10.1016/j.jcv.2007.02.001. PubMed
351 PMID: 17376739.

352

Figure 1.




Table 1. Specificity of dry loop-mediated isothermal amplification assay for SARS-CoV-2.

Virus	Name of isolate	Amount (copies / reaction)
Coronaviruses		
	SARS-CoV Frankfurt-1	4.00×10^7
	MERS-CoV EMC	1.00×10^5
Human coronaviruses (HCoV)		
	HCoV-HKU1 Tokyo/SGH-15/2014	6.00×10^6
	Tokyo/SGH-18/2016	1.00×10^6
	HCoV-OC43 VR-1558	4.00×10^8
	Tokyo/SGH-36/2014	3.00×10^6
	Tokyo/SGH-61/2014	1.00×10^7
	Tokyo/SGH-6/2015	4.00×10^6
	Tokyo/SGH-65/2016	1.00×10^7
	HCoV-NL63 Amsterdam I	8.00×10^7
	Tokyo/SGH-15/2017	1.00×10^5
	Tokyo/SGH-24/2018	4.00×10^4
	HCoV-229E VR-740	7.00×10^7
	Sendai-H/1121/04	1.00×10^6
	Niigata/01/08	1.00×10^5
Influenza virus		
	A A/Texas/50/2012(H3N2)	1.18×10^6
	A/Narita/1/2009(H1N1)	2.94×10^6
	B B/Massachusetts/2/2012	4.44×10^6
	B/Texas/2/2013	1.46×10^7
	B/Brisbane/60/2008	2.00×10^5
Respiratory syncytial virus (RSV)		
	A2	1.00×10^6
	B1	1.00×10^6

Table 2. Comparison of real-time RT-PCR and dry loop-mediated isothermal amplification assay results of SARS-CoV-2 using clinical specimens.

Case	Sampling day*	Real-time RT-PCR (copies/ reaction)	LAMP
1	unknown**	212732.5	+
2	unknown**	94749.3	+
3	7	22910.9	+
4	5	3796.9	+
5	11	1544.6	+
6	10	946.9	+
7	8	413.9	+
8	8	280.8	+
9	9	146.0	+
10	unknown**	68.7	+
11	12	49.8	+
12	12	48.9	+
13	7	14.2	+
14	8	13.2	+
15	19	4.4	+
16	7	2.6	-
17	18	2.3	-
18	10	2.2	-
19	20	0.5	-
20	14	0.0	-
21	8	0.0	-
22	12	0.0	-
23	10	0.0	-
24	12	0.0	-

* Onset of disease was defined as day 1.

** Sampling day was unknown because the patient was asymptomatic.